Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

NCT00138632 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Wet Age-Related Macular Degeneration

Interventions

DRUG: PTK787
DRUG: PTK787
DRUG: Placebo

Sponsor

Novartis